Sharekhan

Dr Lal Pathlabs Ltd

Wed 21/05/2025,15:57:20 | NSE : LALPATHLAB

₹ 2835.2013.90 (0.49%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 2835.00

Previous Close

₹ 2821.30

Volume

154824

Mkt Cap ( Rs. Cr)

₹23699.93

High

₹ 2885.00

Low

₹ 2803.50

52 Week High

₹ 3653.95

52 Week Low

₹ 2293.55

Book Value Per Share

₹ 239.45

Dividend Yield

0.85

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Dr Lal Pathlabs Ltd

Your Vote -

Buy

74.53%

Hold

3.73%

Sell

21.74%

74.53%

161 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

2835.20

124

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

124

Option Chain

Analyzes market sentiment, predicts Dr Lal Pathlabs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Dr. Lal Pathlabs Ltd - Disclosure under SEBI Takeover Regulations

    19 May 2025, 11:35PM (Hony) Brig. Dr. Arvind Lal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (S
  • Dr. Lal Pathlabs Ltd - Amended Trust Deed

    19 May 2025, 4:16PM Attached
  • Dr. Lal Pathlabs Ltd - Updates

    19 May 2025, 4:12PM Pursuant to Regulation 3(3) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, please find enclosed herewith duly execute
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    19 May 2025, 9:51AM Attached
  • Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    19 May 2025, 9:47AM Dr. Lal Path Labs Ltd. has informed the Exchange about Schedule of meet
  • Dr. Lal Pathlabs Ltd has declared 60% Final dividend for the financial year March 2025

    16 May 2025, 3:20PM Dr. Lal Pathlabs Ltd. on Friday, 25 April 2025, has announced Final dividend of 60 percent on Equity Share, to its shareholders holding shares on the
  • Dr. Lal Pathlabs Ltd - Copy of Newspaper Publication

    8 May 2025, 11:11AM Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication
  • Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    1 May 2025, 4:58PM Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    1 May 2025, 5:03PM Attached
  • Dr. Lal Pathlabs Ltd - Copy of Newspaper Publication

    26 Apr 2025, 11:38AM Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication
  • Dr. Lal Pathlabs Ltd - Outcome of Board Meeting-XBRL

    25 Apr 2025, 8:21PM Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on 25-Apr-2025 for Dividend
  • Dr. Lal Pathlabs Ltd - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    25 Apr 2025, 8:15PM DR. LAL PATH LABS LTD. has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agen
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    25 Apr 2025, 8:05PM Attached
  • Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    25 Apr 2025, 8:02PM Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Investor Presentation

    25 Apr 2025, 3:02PM Earnings Presentation on Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2025
  • Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    25 Apr 2025, 3:01PM Dr. Lal Path Labs Ltd. has informed the Exchange about Presentation
  • Dr. Lal Pathlabs Ltd - Press Release

    25 Apr 2025, 2:58PM Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated April 25, 2025, titled ""Audited Financial Results (Standalone and Co
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    25 Apr 2025, 2:56PM Press Release on the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2025
  • Dr. Lal Pathlabs Ltd Q4 net profit jumps 65.81% at Rs 148.40 cr

    25 Apr 2025, 2:40PM The company reported standalone net profit of Rs 148.40 crore for the quarter ended March 31, 2025 as compared to Rs 89.50 crore in the same period la
  • Dr. Lal Pathlabs Ltd - Annual General Meeting

    25 Apr 2025, 2:37PM Attached
  • Dr. Lal Pathlabs Ltd - General Updates

    25 Apr 2025, 2:36PM Dr. Lal Path Labs Ltd. has informed the Exchange about Annual General Meeting (AGM) to be held on June 28, 2025
  • Dr. Lal Pathlabs Ltd - Appointment Of Auditors Viz. Internal Auditor, Cost Auditor And Secretarial Auditor

    25 Apr 2025, 2:35PM Attached
  • Dr. Lal Pathlabs Ltd - General Updates

    25 Apr 2025, 2:33PM Dr. Lal Path Labs Ltd. has informed the Exchange about Appointment of Auditors viz. Internal Auditor, Cost Auditor and Secretarial Auditor.
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Change in Directorate

    25 Apr 2025, 2:33PM Re-appointment of Independent Directors
  • Dr. Lal Pathlabs Ltd - Record Date For Final Dividend For The Financial Year Ended March 31, 2025

    25 Apr 2025, 2:31PM Attached
  • Dr. Lal Pathlabs Ltd - Change in Director(s)

    25 Apr 2025, 2:31PM Dr. Lal Path Labs Ltd. has informed the Exchange regarding Change in Director(s) of the company.
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Dividend Updates

    25 Apr 2025, 2:28PM Attached
  • Dr. Lal Pathlabs Ltd - Record Date

    25 Apr 2025, 2:27PM Dr. Lal Path Labs Ltd. has informed the Exchange that Record date for the purpose of Dividend is 06-Jun-2025.
  • Dr. Lal Pathlabs Ltd - Board Meeting Outcome for Outcome Of Board Meeting Dated April 25, 2025

    25 Apr 2025, 2:25PM Attached
  • Dr. Lal Pathlabs Ltd - Outcome of Board Meeting

    25 Apr 2025, 2:24PM Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on April 25, 2025.
  • Dr. Lal Pathlabs Ltd - Dividend

    25 Apr 2025, 2:23PM Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on April 25, 2025, recommended Final Dividend of Rs. 6 pe
  • Dr. Lal Pathlabs Ltd - Financial Results For The Quarter And Financial Year Ended March 31, 2025

    25 Apr 2025, 2:21PM Attached
  • Dr. Lal Pathlabs Ltd - Outcome of Board Meeting

    25 Apr 2025, 2:19PM Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on April 25, 2025.
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Credit Rating

    22 Apr 2025, 7:24PM Attached
  • Dr. Lal Pathlabs Ltd - Credit Rating

    22 Apr 2025, 7:22PM Dr. Lal Path Labs Ltd. has informed the Exchange about Credit Rating
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    21 Apr 2025, 6:33PM Attached
  • Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    21 Apr 2025, 6:29PM Dr. Lal Path Labs Ltd. has informed the Exchange about Schedule of meet
  • Dr. Lal Pathlabs Ltd - Trading Window-XBRL

    18 Apr 2025, 10:41AM DR. LAL PATH LABS LTD. has informed the Exchange about Closure of Trading Window
  • Dr. Lal Pathlabs Ltd - Board Meeting Intimation

    18 Apr 2025, 10:39AM DR. LAL PATH LABS LTD. has informed the Exchange about Board Meeting to be held on 25-Apr-2025 to consider and approve the Yearly Audited Financial re
  • Dr. Lal Pathlabs Ltd - Board Meeting Intimation for Considering And Approving The Audited Financial Results Of The Company Fo

    18 Apr 2025, 10:28AM Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2025 ,inter alia, to consider and
  • Dr. Lal Pathlabs Ltd - Press Release

    15 Apr 2025, 10:42AM Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated April 15, 2025, titled ""Dr. Lal PathLabs Becomes South Asia s First
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    15 Apr 2025, 10:45AM Press Release attached
  • Dr. Lal Pathlabs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    12 Apr 2025, 7:00PM As of March 2025, 53.91% is owned by Promoters, 45.83% by Public and 0.27% by Non Promoters-Non Public. <p align=justify> Among Promoters holding, Ind
  • Dr. Lal Pathlabs Ltd - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    11 Apr 2025, 7:08PM Certificate Attached
  • Dr. Lal Pathlabs Ltd - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    11 Apr 2025, 7:05PM Dr. Lal Path Labs Ltd. has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Dr. Lal Pathlabs Ltd - Grant Of Stock Options

    9 Apr 2025, 5:21PM Disclosure Attached
  • Dr. Lal Pathlabs Ltd - ESOP/ESOS/ESPS

    9 Apr 2025, 5:17PM Dr. Lal Path Labs Ltd. has informed the Exchange regarding Grant of 168500 Options.
  • Dr. Lal Pathlabs Ltd - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    31 Mar 2025, 7:58PM Dr. Lal Path Labs Ltd. has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agen
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Change in Directorate

    31 Mar 2025, 7:48PM Disclosure attached
  • Dr. Lal Pathlabs Ltd - Cessation

    31 Mar 2025, 7:43PM Dr. Lal Path Labs Ltd. has informed the Exchange that Dr. Om Prakash Manchanda (DIN: 02099404), stepped down as Managing Director (KMP) and ceased as
  • Dr. Lal Pathlabs Ltd - Trading Window-XBRL

    25 Mar 2025, 10:13AM DR. LAL PATH LABS LTD. has informed the Exchange about Closure of Trading Window
  • Dr. Lal Pathlabs Ltd - Trading Window

    25 Mar 2025, 10:07AM Dr. Lal Path Labs Ltd. has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2
  • Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Mar 2025, 12:26PM Dr. Lal Path Labs Ltd. has informed the Exchange about Schedule of meet
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 Mar 2025, 12:30PM Intimation of Schedule of Analyst/ Institutional Investor Meeting(s)
  • Dr. Lal Pathlabs Ltd - Update-Acquisition/Scheme/Sale/Disposal-XBRL

    19 Mar 2025, 12:27PM Dr. Lal Path Labs Ltd. has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
  • Dr. Lal Pathlabs Ltd - Update On Voluntary Liquidation Of Suburban Diagnostics (India) Private Limited (A Wholly Owned Subsid

    18 Mar 2025, 11:15PM Attached
  • Dr. Lal Pathlabs Ltd - General Updates

    18 Mar 2025, 11:12PM Dr. Lal Path Labs Ltd. has informed the Exchange about Update on Voluntary Liquidation of Suburban Diagnostics (India) Private Limited, Wholly Owned S
  • Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Credit Rating

    14 Mar 2025, 10:49AM Intimation of withdrawal of Credit Rating at the Company's request
  • Dr. Lal Pathlabs Ltd - Credit Rating- Others

    14 Mar 2025, 10:44AM Dr. Lal Path Labs Ltd. has informed the Exchange about withdrawal of Credit Rating by CARE Ratings
  • Dr. Lal Pathlabs Ltd - Shareholders meeting

    10 Mar 2025, 5:46PM Dr. Lal Path Labs Ltd. has submitted the Exchange a copy Srutinizers report and voting results of Postal Ballot
  • Dr. Lal Pathlabs Ltd - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    10 Mar 2025, 5:33PM Intimation of Results of Postal Ballot along with Scrutinizer's Report
  • Dr Lal Pathlabs

    24 Oct 2024 , 11:22AM Revenue rose 9.8% to Rs 660 crore versus 601 crore (estimate: Rs 670 crore). Ebitda was up 14% to Rs 202.50 crore versus Rs 178 crore (estimate: Rs 195 crore). Net Profit up 18% at Rs 130.80 crore versus 111 crore (Estimate: Rs 125 crore). Positive
  • Dr. Lal PathLabs

    10 Jan 2023 , 11:02AM Dr. Lal PathLabs is planning to take on a leadership position in Western India, a market the company is investing significantly for. Its subsidiary Suburban Diagnostics has opened its largest reference lab in Vidyavihar, Mumbai, which is expected to ramp up testing capabilities and volumes significantly in coming months for the company. The Mumbai reference or apex lab built with an investment of Rs. 15-16 crore is fourth such apex lab for Dr. Lal PathLabs in India and will expand its tests menu from 750 to 2,800 diagnostic tests and later up to 4,500 such tests. Our view: It is Positive as it expands its capacity to perform higher volumes of tests. We do not have coverage on Dr. LalPathlabs.
  • Metropolis, Dr Lal Pathlabs, Thyrocare Technologies

    7 Dec 2021 , 11:01AM The Government of Maharashtra has revised downwards the RT-PCR tests costs to RS 500 for a tests done in a laboratory or a hospital and Rs 700 for a home collection sample. This is the sixth time the rates of the RT-PCR tests has been slashed from 4500 in June 2020 to RS 500 now. Also the costs for bulk testing by Government agencies has been fixed at Rs 350 as compared to Rs 500 earlier. Post the easing of the second wave of Covid, the share of RT-PCR tests had reduced substantially and hence this is unlikely to have any material impact on the financial performance of the diagnostic companies.
  • Metropolis Healthcare, Dr Lal Pathlabs, Thyrocare Technologies

    29 Nov 2021 , 11:29AM In the light of the likely hike in the Covid cases, especially for the new identified variant – Omicron, there could be a possibility of higher covid tests and this could be positive for diagnostic players such as Metropolis Healthcare, Dr Lal Pathlabs, Thyrocare amongst Others.
  • Metropolis, Dr Lal Path labs, Thyrocare

    15 Jun 2020 , 9:42AM Maharashtra has announced that it would slash the rates of of COVID-19 RT PCR test to half. The state government has set a maximum price of Rs 2,200 for standard collection of swab and the report, and Rs 2,800 for home collection. The lowering of the rates could result in higher no of tests done given the increasing no if Covid cases in the state.

Key fundamentals

Evaluate the intrinsic value of Dr Lal Pathlabs Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 2134.2 1982.996 1926.535 1821.892 1217.085
Liabilities 2134.2 1982.996 1926.535 1821.892 1217.085
Equity 83.6 83.478 83.368 83.345 83.345
Gross Profit 665.5 559.24 460.701 510.217 407.38
Net Profit 497.3 384.37 292.358 344.054 280.106
Cash From Operating Activities 540 477.599 427.531 423.81 373.357
NPM(%) 21.14 19.54 16.52 18.37 18.79
Revenue 2351.6 1966.758 1769.03 1872.706 1490.555
Expenses 1686.1 1407.518 1308.329 1362.489 1083.175
ROE(%) 24.84 19.2 14.6 17.18 13.99

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
06 Jun 2025 6 60 0.85 2911.2
05 Feb 2025 6 60 0.85 2877.85
05 Nov 2024 6 60 0.85 3255.7
20 Aug 2024 6 60 0.85 3274.6
10 Jun 2024 6 60 0.85 2347.9
13 Feb 2024 12 120 0.85 2499.6
11 Aug 2023 6 60 0.85 1906.35
05 Aug 2022 6 60 0.85 2144.5
22 Jun 2022 6 60 0.85 2184.6
18 Aug 2021 6 60 0.85 3556.35
20 Jul 2021 8 80 0.85 2830.9
09 Feb 2021 6 60 0.85 2247.5
18 Nov 2020 6 60 0.85 2318.65
05 Mar 2020 6 60 0.85 1649.75
20 Nov 2019 6 60 0.85 1452.9
02 Aug 2019 3.5 35 0.85 1065.35
19 Nov 2018 2.5 25 0.85 880.5
03 Aug 2018 3 30 0.85 807.1
20 Nov 2017 1.5 15 0.85 833.75
12 Jul 2017 1.7 17 0.85 891.15
13 Feb 2017 1.3 13 0.85 1082.3
20 Jul 2016 2.45 24.5 0.85 941.5

Peers

Other companies within the same industry or sector that are comparable to Dr Lal Pathlabs Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.15 -0.84 26.88 1609.52 301.39 0.62
Lotus Eye Hospital and Institute Ltd 74.06 0.78 308.58 5864.87 14.01 0.68
Vaishali Pharma Ltd 12.85 -1.15 428.33 3022.98 2.76 0.00
Astec Lifesciences Ltd 701.25 -1.59 0.00 5530.07 -687.11 0.00

Company Info

Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently, Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory', pursuant to a partnership deed dated March 21, 1975, with the partnership deemed to have commenced from December 1, 1974. The partnership firm was formed to provide pathology services under the name `Central Clinical Laboratory' and to maintain a blood bank for the supply of blood to patients and hospitals under the name `Blood Transfusion Centre', both to be undertaken at the Registered Office of the Company. On December 5, 1977, following the demise of Late Dr. Major S.K. Lal, Late Ms. Vimla Lal, wife of Late Dr. Major S.K. Lal, was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal's demise, Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2, 2007. Accordingly, as on date, Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as `Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7, 2015. Consequently, the name of the Company was changed to `Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. Awards and accreditations : 2001 -Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials. 2002 -Fully accredited by the College of American Pathologists' Laboratory Accreditation Program. 2008 -Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010 -Franchisor of the Year in healthcare, at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012 -Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013 -Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014 -Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories - Requirements for Quality and Competence" for medical testing, for National Reference Laboratory. 2015 -Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India. Major events and milestones : 2005 & 2007 -Investment by WestBridge I Investments Holdings. 2008 -Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013 -Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013 -Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014 -Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015 -Amalgamation of Sanya Chemicals Private Limited, Amolak Diagnostics Private Limited, Medex Healthcare Private Limited, Medicave Diagnostic Centre Private Limited, Medicave Medical Systems Private Limited and the Company. 2016 -Dr Lal PathLabs Presents First Trimester Screening Test for Screening Prenatal Disorders -Dr Lal PathLabs Enhanced Liver Fibrosis Test For Mapping Liver Functionality -Dr Lal PathLabs is the First Private Lab in India to Introduce Electron Microscopy 2017 -Dr Lal PathLabs is Amalgameted with Ria and Pathology Private Limited 2018 -Amalgamation of Shree Computerised Pathology Laboratory, Modern Diagnostics & Modern Lab 2021 -Dr Lal PathLabs Launches Bangalore Reference Laboratory. 2023 -NCLT has given approval for Amalgamation between Dr. Lal PathLabs Limited and APL Institute of Clinical Laboratory & Research Private Limited. 2024 -NCLT, Allahabad Bench sanctioned the Scheme of Amalgamation between two Subsidiary Companies of Dr. Lal PathLabs Limited.

Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently, Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory', pursuant to a partnership deed dated March 21, 1975, with the partnership deemed to have commenced from December 1, 1974. The partnership firm was formed to provide pathology services under the name `Central Clinical Laboratory' and to maintain a blood bank for the supply of blood to patients and hospitals under the name `Blood Transfusion Centre', both to be undertaken at the Registered Office of the Company. On December 5, 1977, following the demise of Late Dr. Major S.K. Lal, Late Ms. Vimla Lal, wife of Late Dr. Major S.K. Lal, was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal's demise, Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2, 2007. Accordingly, as on date, Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as `Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7, 2015. Consequently, the name of the Company was changed to `Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. Awards and accreditations : 2001 -Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials. 2002 -Fully accredited by the College of American Pathologists' Laboratory Accreditation Program. 2008 -Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010 -Franchisor of the Year in healthcare, at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012 -Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013 -Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014 -Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories - Requirements for Quality and Competence" for medical testing, for National Reference Laboratory. 2015 -Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India. Major events and milestones : 2005 & 2007 -Investment by WestBridge I Investments Holdings. 2008 -Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013 -Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013 -Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014 -Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015 -Amalgamation of Sanya Chemicals Private Limited, Amolak Diagnostics Private Limited, Medex Healthcare Private Limited, Medicave Diagnostic Centre Private Limited, Medicave Medical Systems Private Limited and the Company. 2016 -Dr Lal PathLabs Presents First Trimester Screening Test for Screening Prenatal Disorders -Dr Lal PathLabs Enhanced Liver Fibrosis Test For Mapping Liver Functionality -Dr Lal PathLabs is the First Private Lab in India to Introduce Electron Microscopy 2017 -Dr Lal PathLabs is Amalgameted with Ria and Pathology Private Limited 2018 -Amalgamation of Shree Computerised Pathology Laboratory, Modern Diagnostics & Modern Lab 2021 -Dr Lal PathLabs Launches Bangalore Reference Laboratory. 2023 -NCLT has given approval for Amalgamation between Dr. Lal PathLabs Limited and APL Institute of Clinical Laboratory & Research Private Limited. 2024 -NCLT, Allahabad Bench sanctioned the Scheme of Amalgamation between two Subsidiary Companies of Dr. Lal PathLabs Limited.

Read More

Parent Organisation

Dr. Lal Pathlabs Ltd.

Founded

14/02/1995

Managing Director

Dr.Om Prakash Manchanda

NSE Symbol

LALPATHLABEQ

FAQ

The current price of Dr Lal Pathlabs Ltd is ₹ 2835.20.

The 52-week high for Dr Lal Pathlabs Ltd is ₹ 2885.00 and the 52-week low is ₹ 2803.50.

The market capitalization of Dr Lal Pathlabs Ltd is currently ₹ 23699.93. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Dr Lal Pathlabs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Dr Lal Pathlabs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Dr Lal Pathlabs Ltd shares.

The CEO of Dr Lal Pathlabs Ltd is Dr.Om Prakash Manchanda, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT